A prospective study on the cardio-metabolic effects of apremilast in patients with psoriatic arthritis

A prospective study on the cardio-metabolic effects of apremilast in patients with psoriatic arthritis - Aprmilast for psoriatic arthritis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON43353

Enrollment

Registered

2016-10-12

Start date

2017-03-17

Completion date

Unknown

Last updated

2024-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

inflammatory arthritis psoriatic arthritis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Adult (>=18 years) patients with active psoriatic arthritis - Starting apremilast

Exclusion criteria

Exclusion criteria: - Inability or unwillingness to sign informed consent - Contraindication for apremilast (i.e. pregnancy and hypersensitivity to apremilast and/or its excipients)

Design outcomes

Primary

Measure	Time frame
Body composition assessed using whole body DEXA	—

Secondary

Measure	Time frame
Medical history, date of birth, gender, ethnicity, smoking status, use of alcohol, physical activity, date of diagnosis, comorbidity, concomitant medication, use of concomitant and prior DMARDs, height, weight, blood pressure, heart rate, abdominal wall and hip circumference, presence of peripheral arthritis, patient pain VAS, patient global assessment of disease activity (VAS), PASI, LEI, RAPID, ESR, hsCRP, HbA1c (only in patients diagnosed with diabetes mellitus), TC, HDL, LDL, Apo, HDL efflux capacity, glucose, ICAM, VCAM, adiponectines, PCSK9, cIMT, DECT-scan	—

Measure

Time frame

Medical history, date of birth, gender, ethnicity, smoking status, use of alcohol, physical activity, date of diagnosis, comorbidity, concomitant medication, use of concomitant and prior DMARDs, height, weight, blood pressure, heart rate, abdominal wall and hip circumference, presence of peripheral arthritis, patient pain VAS, patient global assessment of disease activity (VAS), PASI, LEI, RAPID, ESR, hsCRP, HbA1c (only in patients diagnosed with diabetes mellitus), TC, HDL, LDL, Apo, HDL efflux capacity, glucose, ICAM, VCAM, adiponectines, PCSK9, cIMT, DECT-scan

—

Countries

Netherlands

Outcome results